{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:30:23Z","timestamp":1783398623713,"version":"3.54.6"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","jdsjournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jdermsci.2021.10.003","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T17:54:47Z","timestamp":1634234087000},"page":"177-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1\u03b3 antibodies"],"prefix":"10.1016","volume":"104","author":[{"given":"Nhung Thi My","family":"Ly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuko","family":"Ueda-Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuyen Thi Hong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Anada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jdermsci.2021.10.003_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J. Am. A. Dermatol."},{"issue":"9","key":"10.1016\/j.jdermsci.2021.10.003_bib2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.7326\/0003-4819-122-9-199505010-00010","article-title":"NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy","volume":"122","author":"Plotz","year":"1995","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jdermsci.2021.10.003_bib3","doi-asserted-by":"crossref","first-page":"116s","DOI":"10.1038\/jid.1993.34","article-title":"Humoral immunity in polymyositis\/dermatomyositis","volume":"100","author":"Targoff","year":"1993","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jdermsci.2021.10.003_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"Journal of Internal Medicine"},{"issue":"1","key":"10.1016\/j.jdermsci.2021.10.003_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"Overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"10.1016\/j.jdermsci.2021.10.003_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12016-015-8513-8","article-title":"The clinical features of myositis-associated autoantibodies: a review","volume":"52","author":"Gunawardena","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.jdermsci.2021.10.003_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1203475416665601","article-title":"Risk of malignancy in dermatomyositis and polymyositis","volume":"21","author":"Qiang","year":"2017","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.jdermsci.2021.10.003_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.semarthrit.2015.06.005","article-title":"Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort","volume":"45","author":"Dobloug","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.jdermsci.2021.10.003_bib9","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jdermsci.2021.10.003_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","article-title":"Identification of a novel autoantibody reactive with 155 and 140\u2009kDa nuclear proteins in patients with dermatomyositis: an association with malignancy","volume":"46","author":"Kaji","year":"2006","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.jdermsci.2021.10.003_bib11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jdermsci.2021.10.003_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cell.2005.01.033","article-title":"Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase","volume":"121","author":"Dupont","year":"2005","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.jdermsci.2021.10.003_bib13","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jdermsci.2021.10.003_bib14","first-page":"1","article-title":"Transcriptional intermediary factor 1 (TIF1) and anti-TIF1gamma antibody-positive dermatomyositis","author":"Kotobuki","year":"2020","journal-title":"Immunol Med"},{"issue":"2","key":"10.1016\/j.jdermsci.2021.10.003_bib15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jdermsci.2021.10.003_bib16","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/BOR.0b013e3283317fa5","article-title":"Paraneoplastic myopathy","volume":"21","author":"Dank\u00f3","year":"2009","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.jdermsci.2021.10.003_bib17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13075-018-1650-8","article-title":"Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis","volume":"20","author":"Krystufkova","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.jdermsci.2021.10.003_bib18","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/1346-8138.15117","article-title":"Elevated serum B-cell activating factor levels in patients with dermatomyositis: association with interstitial lung disease","volume":"46","author":"Matsushita","year":"2019","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.jdermsci.2021.10.003_bib19","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s100670070027","article-title":"Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis","volume":"19","author":"Shimizu","year":"2000","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.jdermsci.2021.10.003_bib20","first-page":"410","article-title":"Dermatomyositis and polymyositis: new treatment targets on the horizon","volume":"69","author":"Hak","year":"2011","journal-title":"Neth J Med"},{"issue":"7","key":"10.1016\/j.jdermsci.2021.10.003_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jdermsci.2021.10.003_bib22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jdermsci.2021.10.003_bib23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00002281-199911000-00005","article-title":"Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis","volume":"11","author":"Sontheimer","year":"1999","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.jdermsci.2021.10.003_bib24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2133.2009.09521.x","article-title":"Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument","volume":"162","author":"Yassaee","year":"2010","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jdermsci.2021.10.003_bib25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjd.15140","article-title":"The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists","volume":"176","author":"Tiao","year":"2017","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jdermsci.2021.10.003_bib26","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/ard.2006.068502","article-title":"The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis","volume":"66","author":"Chinoy","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jdermsci.2021.10.003_bib27","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jdermsci.2021.10.003_bib28","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/1346-8138.15284","article-title":"Clinical significance of serum levels of anti-transcriptional intermediary factor 1-\u03b3 antibody in patients with dermatomyositis,","volume":"47","author":"Ikeda","year":"2020","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jdermsci.2021.10.003_bib29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/rheumatology\/kez572","article-title":"Langhe, Anti-TIF1-\u03b3 autoantibodies: warning lights of a tumour autoantigen","volume":"59","author":"De Vooght","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.jdermsci.2021.10.003_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/400_2008_26","article-title":"The role of TNF in cancer","volume":"49","author":"Wajant","year":"2009","journal-title":"Results Probl Cell Differ"},{"key":"10.1016\/j.jdermsci.2021.10.003_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/369432","article-title":"Bleecker, The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy","volume":"2012","author":"De Paepe","year":"2012","journal-title":"Clinical & developmental immunology"},{"issue":"3","key":"10.1016\/j.jdermsci.2021.10.003_bib32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.semarthrit.2006.07.003","article-title":"Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications","volume":"36","author":"Efthimiou","year":"2006","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.jdermsci.2021.10.003_bib33","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3899\/jrheum.140977","article-title":"Increased Serum B Cell Activating Factor and a Proliferation-inducing Ligand Are Associated with Interstitial Lung Disease in Patients with Juvenile Dermatomyositis, The","volume":"42","author":"Kobayashi","year":"2015","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1016\/j.jdermsci.2021.10.003_bib34","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/art.24555","article-title":"Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy","volume":"60","author":"Niewold","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1-2","key":"10.1016\/j.jdermsci.2021.10.003_bib35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"issue":"11","key":"10.1016\/j.jdermsci.2021.10.003_bib36","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jdermsci.2021.10.003_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"Plos One"},{"issue":"4","key":"10.1016\/j.jdermsci.2021.10.003_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14976","article-title":"The effects of infliximab in treating idiopathic inflammatory myopathies: A review article","volume":"34","author":"Ge","year":"2021","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.jdermsci.2021.10.003_bib39","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jdermsci.2021.10.003_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818817293","article-title":"Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment?","volume":"12","author":"Sebastian","year":"2019","journal-title":"Therap Adv Gastroenterol"}],"updated-by":[{"DOI":"10.1016\/j.jdermsci.2022.06.003","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000}}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181121002449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181121002449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T11:29:54Z","timestamp":1642159794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181121002449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0923181121002449"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2021.10.003","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1\u03b3 antibodies","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2021.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V. on behalf of Japanese Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}